DATES: Comments on this ICR should be received no later than September 18, 2023.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under Review—Open for Public Comments'' or by using the search function.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, email *paperwork@hrsa.gov* or call Samantha Miller, the HRSA Information Collection Clearance Officer, at (301) 443–3983.

SUPPLEMENTARY INFORMATION:

Information Collection Request Title: Forms for Use with Applications to the Maternal and Child Health Bureau Research Grants, OMB 0906—Reinstatement

Abstract: HRSA is requesting reinstatement of the Biographical Sketch Form for use with applications to the Maternal and Child Health Bureau Research Grants (Biographical Sketch) for HRSA's SF424 Research & Related application package. These grants are funded by a number of authorities such as 42 U.S.C. 701(a)(2) (title V, 501(a)(2) of the Social Security Act) and by 42 U.S.C. 280i–1(f) (title III, section 399BB(f) of the Public Health Service Act. The purpose of these grants is to advance the health and well-being of Maternal and Child Health populations and children and adolescents with autism spectrum disorder by supporting innovative, applied, and translational intervention research studies on critical issues affecting these populations.

A 60-day notice published in the **Federal Register** on March 1, 2023, vol. 88, No. 40; pp. 12953–54. There were no public comments.

Need and Proposed Use of the Information: HRSA plans to use the Biographical Sketch as a required element of the SF424 Research & Related application package. The applicants use the Biographical Sketch form to summarize the qualifications of each key personnel on their proposed research team, including education/training, positions and honors, contributions to science, and related experience. The grant reviewers will use this information to assess the capabilities of the research team to carry out the planned research project. The Biographical Sketch form also collects demographic data for the Principal Investigator and key program staff. HRSA is considering several changes for the Biographical Sketch:

- *Clarifying instructions:* Provides the applicant more information on what should and should not be included on the biographical sketch.
- *Removal of Section D:* Section D: Related Experience has been removed.
- *Removal of Section E:* Section E: Additional Information: Research Support and/or Scholastic Performance Awards has been removed.
- ''*Some Other Race*'' *Category:* At the request of our applicants, this category was added.

Likely Respondents: Respondents are applicants to HRSA's Maternal and Child Health Bureau research programs.

Burden Statement: Burden includes the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, disclosing and providing information. It also accounts for time to train personnel, respond to a collection of information, search data sources; complete and review the collection of information, and transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

Total Estimated Annualized Burden Hours:

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
Biographical Sketch Form	200	5	1,000	1.75	1,750
Total	200	5	1,000	1.75	1,750

Amy P. McNulty,

Deputy Director, Executive Secretariat.

[FR Doc. 2023–17636 Filed 8–16–23; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice; Licensing and Collaboration Opportunity

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is directed to potential peptidyl therapeutics that counteract with amyloid forming IAPP and amyloid-β in treatments of diabetes and Alzheimer's disease and serve as blood-based biomarkers for Alzheimer's disease. This technology was discovered and is being developed by the National Institute on Aging (NIA). The NIA is currently seeking a licensee and/or collaborator to further develop this technology.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing and collaboration opportunity should be directed to: Zarpheen Jinnah, Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850–9702 Telephone: (240) 276–5530; Facsimile: (240) 276–5504 Email: *zarpheen.jinnah@nih.gov.* A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to this invention.

SUPPLEMENTARY INFORMATION: The following patent application is available for licensing and/or collaboration under a Cooperative Research and Development Agreement (CRADA):

U.S. Provisional Application No. 63/417,582.

Achieving expeditious commercialization of federally funded research and development is consistent with the goals of the Bayh-Dole Act, codified as 35 U.S.C. 200–212.

Background and Description of Technology: Over 34 million Americans are living with diabetes and an estimated 6.5 million Americans are living with Alzheimer's disease (AD). A

hallmark feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Amyloidosis due to aggregation of amyloid-β is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide ($IAPP_{37}$) in human islet leads to β-cell dysfunction. Researchers at NIA used a bioinformatic approach to identify two novel islet amyloid polypeptide isoforms: IAPPβ, encoding an elongated propeptide and non-aggregating IAPPγ, which is processed to mature $IAPP_{25}$ instead of $IAPP_{37}$. They developed a quantitative selective reaction monitoring (SRM) proteomic assay to measure the isoform peptide levels in human clinical plasma and CSF from individuals with early AD and found that their levels were significantly reduced. Further, mature $IAPP_{25}$ derived from IAPPγ isoform inhibits fibrillation of IAPP and amyloid-β efficiently *in vitro.*

Potential Commercial Applications: The novel IAPPβ and IAPPγ isoforms are potential peptidyl therapeutics to counteract with amyloid forming IAPP and amyloid-β in treatments of diabetes and Alzheimer's disease and serve as blood-based biomarkers for Alzheimer's disease.

Competitive Advantages:

- Peptide based anti-amyloid medicine.
- Potential market applications for neurodegenerative diseases.

Development Stage: Pre-clinical (*in vivo* validation).

Publications: Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer's Disease and Inhibitors of Amyloid Formation. (PMID 36671553) at *https://pubmed.ncbi.nlm.nih.gov/36671553/.*

Meng, Lanxia, et al. Islet amyloid polypeptide triggers α-synuclein pathology in Parkinson's disease. (PMID 37150314)

Dated: August 11, 2023.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2023–17673 Filed 8–16–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Human Genome Research Institute Initial Review Group; Genome Research Study Section GNOM–G—CEGS.

Date: November 2–3, 2023.

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Room 3180, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Sarah Jo Wheelan, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Room 3180, Bethesda, MD 20892, (301) 402–8823, *wheelansj@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: August 14, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–17713 Filed 8–16–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Mental Health.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute Of Mental Health, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors; National Institute of Mental Health.

Date: September 20–22, 2023.

Time: September 20, 2023, 1:00 p.m. to 5:15 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892.

Time: September 21, 2023, 10:00 a.m. to 5:55 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892.

Time: September 22, 2023, 10:00 a.m. to 3:10 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892.

Contact Person: Jennifer E. Mehren, Ph.D., Scientific Advisor, Division of Intramural Research Programs, National Institute of Mental Health, NIH, 35A Convent Drive, Room GE 412, Bethesda, MD 20892–3747, 301–496–3501, *mehrenj@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: August 14, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–17711 Filed 8–16–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Collaboration Opportunity To Develop a Vaccine Against Nicotine or Arecoline

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The Cancer Prevention Program of the National Cancer Institute (NCI) is seeking a partner in the private